School of Medicine


Showing 31-40 of 123 Results

  • Jessica E. Gonzalez

    Jessica E. Gonzalez

    Soc Science Rsch Prof 3, Psych/Public Mental Health & Population Sciences

    BioJessica E. Gonzalez, MSW is the Associate Director for the Mental Health Technology Transfer Center (MHTTC) Network Coordinating Office (NCO). The MHTTC NCO is part of the Center for Dissemination and Implementation (CDI) in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine. Through the MHTTC School Mental Health Initiative, Jessica is coordinating the work of 12 centers that provide training and technical assistance to the mental health and school mental health workforce to increase the use of evidence-based mental health prevention, treatment, and recovery support services for students across the United States.

    Jessica has worked in the community as a social worker providing mental health services in school and outpatient clinic settings to children and adolescents of diverse socioeconomic, cultural and ethnic backgrounds. In addition, she has over 10 years of experience in project management and coordination for research and evaluation in the areas of early childhood learning and development, special education, post-secondary education attainment, and delivery of school mental health services. Jessica has also worked for several high school and college programs in the area seeking to improve educational outcomes for first-generation and low-income students of color.

  • Cheryl Gore-Felton, Ph.D.

    Cheryl Gore-Felton, Ph.D.

    Walter E. Nichols, MD Professor in the School of Medicine

    Current Research and Scholarly InterestsMy clinical focus is the treatment of anxiety disorders, including post traumatic stress disorder. My research focuses on developing effective psychotherapy interventions to reduce chronic stress as well as enhance positive health behaviors to reduce morbidity and mortality among patients coping with chronic, medical illnesses which are often life threatening.

  • Heather Gotham

    Heather Gotham

    Clinical Professor, Psychiatry and Behavioral Sciences

    Current Research and Scholarly InterestsDr. Gotham’s research focuses on implementation science, including factors affecting implementation, and training and education of health care providers, across a range of evidence-based practices for adolescent and adult substance use and mental health disorders, co-occurring mental health and substance use disorders, and screening, brief intervention, and referral to treatment (SBIRT).

  • Laura Michele Hack

    Laura Michele Hack

    Assistant Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)

    BioDr. Laura Hack is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences, Director of Novel & Precision Neurotherapeutics at the Stanford Center for Precision Mental Health and Wellness, Director of the Stanford Translational Precision Mental Health Clinic, and Deputy Director of the Precision Neuromodulation Clinic (PNC) within the VA Palo Alto Health Care System. Dr. Hack's translational research program focuses on identifying bioclinical subtypes of depression and comorbid stress-related disorders and testing mechanistically-guided treatments for these subtypes. Dr. Hack studies treatments spanning repurposed medications, such as pramipexole and guanfacine, neuromodulation techniques, ketamine, MDMA, and psilocybin. Clinically, she specializes in delivering novel treatments, including repetitive transcranial magnetic stimulation (rTMS) and ketamine, to patients suffering from treatment-resistant depression and comorbid stress-related disorders.

  • Haijing Wu Hallenbeck

    Haijing Wu Hallenbeck

    Instructor (Affiliated), Psych/Public Mental Health & Population Sciences
    Staff, Psych/Public Mental Health & Population Sciences

    BioHaijing Hallenbeck, PhD, is a research investigator at the National Center for PTSD Dissemination & Training Division at VA Palo Alto Health Care System. She is also an Instructor (Affiliated) in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine. She received her PhD in Clinical Psychology from Washington University in St. Louis and completed her predoctoral clinical internship and postdoctoral research fellowship at VA Palo Alto Health Care System. Funded by the VA VISN 21 Early Career Award Program, Dr. Hallenbeck's research focuses on PTSD and depression and their impact on psychosocial functioning. She studies how to leverage digital health technology (e.g., mobile apps) and analytic tools (e.g., machine learning) to provide timely and personalized assessments and interventions for these conditions.

    Email: haijing.hallenbeck@stanford.edu

  • Kate Hardy

    Kate Hardy

    Clinical Professor, Psychiatry and Behavioral Sciences

    BioKate Hardy is a California Licensed Psychologist who has specialized in working with individuals with psychosis for over 15 years in both research and clinical settings. Dr. Hardy received her doctorate in clinical psychology from the University of Liverpool, United Kingdom. She has worked in specialist early psychosis services in both the UK and the US, including UCSF’s Prodrome Assessment Research and Treatment (PART) program, where she completed her post-doctoral fellowship, and as Clinical Director for the Prevention and Recovery from Early Psychosis (PREP) program. Dr. Hardy has significant experience in providing CBTp to individuals with early psychosis, and those at risk of developing psychosis, in both individual and group settings and integration of this clinical intervention to broader systems and staff teams. She has led multiple trainings and workshops in CBTp to a wide variety of audiences including community clinicians, psychiatrists, and families, and provides ongoing supervision and consultation in this approach. Dr. Hardy is also involved in the implementation of national strategies to increase dissemination of early psychosis models with the aim of bringing these cutting edge treatments to a broader population.